TrialClinical pharmacokinetics2020

Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.

Nelleke Snelder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.